Bolt Biotherapeutics, Inc.
BOLT· Nasdaq
Released Aug 11, 2026, after the close
10-Q filed Aug 11, 2026, 42 days after period end · 0001193125-26-344597
| Metric | Q2 2026 | Q2 2025 | Q2 2024 | Q2 2023 |
|---|---|---|---|---|
| Revenue | $5.00K | $1.80M | $1.28M | $1.43M |
| Net Income | -$7.46M | -$8.56M | -$21.20M | -$18.06M |
| EPS Diluted |
Bolt Biotherapeutics, Inc. · CIK 1641281 · Engraved from SEC EDGAR
| -$3.88 |
| -$4.46 |
| -$11.12 |
| -$0.48 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.